Coherus BioSciences (CHRS): Partnership Likely in 2H’17 - Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil up around 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Coherus Biosciences (CHRS) PT Raised to $44 at Maxim Group; 'David Delivers a Blow to Goliath - Humira Patent '135 Falls'
May 17, 2017 7:34 AM EDTMaxim Group raised its price target on Coherus Biosciences (NASDAQ: CHRS) to $44.00 (from $43.00) while maintaining a Buy rating after Humira patent '135 (dosing) has been invalidated.
Analyst Jason McCarthy said with '135 out of the picture, they believe Coherus could be first... More
